Fractyl exceeded Street EPS consensus by $0.01 ($-0.13 vs $-0.14) on a pre-revenue base, but the read is entirely driven by pipeline catalysts. Monitor the early Q4 2026 REMAIN-1 Pivotal Cohort topline data — it is the next binary catalyst. Stock may remain range-bound until then, with cash runway into early 2027 limiting near-term financing risk.
Price Chart
Executive Summary
Fractyl Health reported Q2 2026 financial results with a net loss of $25.5M, improved from a $27.9M loss in Q2 2025, driven by a $7.0M reduction in operating expenses. The company reiterated its cash runway into early 2027 and confirmed on-track timelines for the REMAIN-1 Pivotal Cohort topline data in early Q4 2026 and potential FDA De Novo submission in late Q4 2026, supported by one-year Midpoint Cohort data showing durable weight maintenance with Revita. No revenue is reported as the company remains pre-commercial, and the quarter was operationally uneventful relative to prior disclosures.
Key Financial Metrics
Key Facts
- Net loss of $25.5M for Q2 2026 improved from $27.9M in Q2 2025.
- Cash and cash equivalents of $47.1M as of June 30, 2026, from $81.5M at Dec 31, 2025; cash runway reaffirmed into early 2027.
- REMAIN-1 Pivotal Cohort topline 6-month data on track for early Q4 2026; potential FDA De Novo submission in late Q4 2026.
- One-year randomized REMAIN-1 Midpoint data showed Revita patients maintained up to 84% of prior GLP-1 weight loss vs 46% sham in optimized population.
- R&D expenses declined to $13.8M from $21.2M year-over-year; operating loss of $19.1M vs $26.1M.
- Adjusted EBITDA improved to -$16.3M from -$24.0M in Q2 2025.
- First-in-human dosing of RJVA-001 still anticipated in H2 2026.
- Total stockholders' deficit of $1.7M as of June 30, 2026, vs $9.5M equity at year-end 2025.
Financial Impact
Net loss narrowed by $2.4M to $25.5M, operating expenses decreased by $7.0M, cash burn of ~$34M Q1+Q2 combined; no revenue.
Risk Factors
- REMAIN-1 Pivotal data may fail to replicate Midpoint Cohort results, particularly in the optimized ablation-length subset.
- FDA De Novo pathway is not guaranteed; pre-submission feedback was non-binding.
- Cash burn rate of ~$17M/quarter; if pivotal data disappoints, financing risk increases sharply.
- Pre-revenue clinical-stage company with no approved products; high binary risk on regulatory outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342343 |
| Document: guts-20260810.htm | 0001193125-26-342343 |
| Document: 0001193125-26-342343-index-headers.html | 0001193125-26-342343 |
| Document: 0001193125-26-342343-index.html | 0001193125-26-342343 |
| Document: 0001193125-26-342343.txt | 0001193125-26-342343 |
| 8-K Data (Synthetic) | 0001193125-26-342343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers